Encyclopedia of Cancer

2011 Edition
| Editors: Manfred Schwab

Pharmacokinetics and Pharmacodynamics in Drug Development

  • Simon Pacey
  • Paul WorkmanEmail author
  • Debashis Sarker
Reference work entry
DOI: https://doi.org/10.1007/978-3-642-16483-5_4501

Definition

Pharmacokinetics

 Pharmacokinetics (PK) is the study of how a drug is absorbed, distributed, metabolized, and excreted over time.

Pharmacodynamics

 Pharmacodynamics (PD) is the study of how a drug affects its target(s) in a dose- and time-dependent fashion.

Characteristics

To maximize the chance of successful drug development, a comprehensive knowledge of the compound under investigation is required. Assuming the drug target has been correctly selected, drug efficacy requires delivery into the patient such that adequate drug concentration is achieved within the plasma and tumor (measured by PK studies) to effect target modulation (measured by PD studies), resulting in anticancer effect(s). These principles have been incorporated into a pharmacological audit trail consisting of a series of questions that should be addressed during drug design and development. These can be summarized as:
  • Is the drug target expressed in the tumor of interest?

  • Are adequate plasma and tumor drug...

This is a preview of subscription content, log in to check access.

References

  1. 1.
    Banerji U, O’Donnell A, Scurr M et al (2005) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23:4152–4161PubMedCrossRefGoogle Scholar
  2. 2.
    Garrett MD, Walton MI, McDonald E et al (2003) The contemporary drug development process: advances and challenges in preclinical and clinical development. Prog Cell Cycle Res 5:145–158PubMedGoogle Scholar
  3. 3.
    Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–715PubMedCrossRefGoogle Scholar
  4. 4.
    Sarker D, Workman P (2007) Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res 96:213–268PubMedCrossRefGoogle Scholar
  5. 5.
    Sarker D, Pacey S, Workman P (2007) Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development. Biomarkers Med 1:399–417CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  1. 1.Cancer Research UK Center for Cancer TherapeuticsThe Institute of Cancer ResearchSurreyUK